- Home
- GYRE vs ULCC Comparison
GYRE vs ULCC Comparison
Compare GYRE & ULCC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GYRE
- ULCC
- Stock Information
- Founded
- GYRE 2002
- ULCC 1994
- Country
- GYRE United States
- ULCC United States
- Employees
- GYRE N/A
- ULCC N/A
- Industry
- GYRE Biotechnology: Pharmaceutical Preparations
- ULCC Air Freight/Delivery Services
- Sector
- GYRE Health Care
- ULCC Consumer Discretionary
- Exchange
- GYRE Nasdaq
- ULCC Nasdaq
- Market Cap
- GYRE 897.1M
- ULCC 765.5M
- IPO Year
- GYRE N/A
- ULCC 2021
- Fundamental
- Price
- GYRE $8.21
- ULCC $4.62
- Analyst Decision
- GYRE
- ULCC Hold
- Analyst Count
- GYRE 0
- ULCC 10
- Target Price
- GYRE N/A
- ULCC $5.17
- AVG Volume (30 Days)
- GYRE 80.3K
- ULCC 4.8M
- Earning Date
- GYRE 08-11-2025
- ULCC 08-05-2025
- Dividend Yield
- GYRE N/A
- ULCC N/A
- EPS Growth
- GYRE N/A
- ULCC N/A
- EPS
- GYRE 0.02
- ULCC N/A
- Revenue
- GYRE $102,189,000.00
- ULCC $3,778,000,000.00
- Revenue This Year
- GYRE $21.04
- ULCC $2.68
- Revenue Next Year
- GYRE $89.64
- ULCC $14.53
- P/E Ratio
- GYRE $170.09
- ULCC N/A
- Revenue Growth
- GYRE N/A
- ULCC 4.60
- 52 Week Low
- GYRE $6.11
- ULCC $2.79
- 52 Week High
- GYRE $19.00
- ULCC $10.26
- Technical
- Relative Strength Index (RSI)
- GYRE 60.94
- ULCC 61.93
- Support Level
- GYRE $6.62
- ULCC $3.27
- Resistance Level
- GYRE $7.47
- ULCC $3.53
- Average True Range (ATR)
- GYRE 0.46
- ULCC 0.32
- MACD
- GYRE 0.12
- ULCC 0.01
- Stochastic Oscillator
- GYRE 99.09
- ULCC 82.58
About GYRE Gyre Therapeutics Inc.
Gyre Therapeutics Inc is a commercial-stage pharmaceutical company developing and commercializing small-molecule anti-inflammatory and anti-fibrotic drugs targeting organ diseases, focusing specifically on organ fibrosis. The company's commercial-stage products include ETUARY, Avatrombopag, and Nintedanib. In addition, it is focused on the development and commercialization of Hydronidone (F351) for the treatment of Metabolic Dysfunction Associated Steatohepatitis (MASH-associated liver fibrosis (MASH fibrosis). Gyre is also advancing a diverse pipeline of different drug candidates in China, including F573, F528, and F230. The company's reportable segments are Gyre Pharmaceuticals, which derives maximum revenue from the sale of ETUARY and certain generic drugs in the PRC, Gyre, and Other.
About ULCC Frontier Group Holdings Inc.
Frontier Group Holdings Inc is an ultra-low-cost carrier whose business is focused on Low Fares Done Right. The company owns a fleet of 120 Airbus single-aisle aircraft, consisting of 13 A320ceos, 82 A320neos, 21 A321ceos and 4 A321neos. The use of these aircraft, their seating configuration, weight-saving tactics, and baggage process have all contributed to the ability to continue to be the fuel-efficient of all the U.S. The Company is managed as a single business unit that provides air transportation for passengers. Majority of revenue is from Domestic flight follow by International.